Back to top

Pantginis Boosts Price Target on NewAmsterdam as Obicetrapib’s Broad Lipid Profile and CV Outcomes Potential Drive Buy Rating

NewAmsterdam Pharma Company, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Pantginis from H.C. Wa...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NewAmsterdam Pharma Company N.V. (NAMS)